Azenta Business Summary

Azenta, Inc. (AZTA) is a pure-play life sciences company specializing in comprehensive sample management and multiomics services. The company generates revenue through two primary segments: Sample Management Solutions (SMS), which accounts for approximately 55% of total sales, and Multiomics, which contributes the remaining 45%. Revenue is derived from the sale of automated cryogenic storage systems, consumables, and lab instruments, as well as recurring service fees from its global biorepository network and genomic services, including next-generation sequencing (NGS) and gene synthesis under the GENEWIZ brand. Azenta occupies a specialized niche in ultra-cold chain automation and sample integrity, competing directly with diversified giants like Thermo Fisher Scientific and Labcorp, as well as specialized peers such as Hamilton Company, Liconic AG, and Twist Bioscience. Originally founded in 1978 as Brooks Automation by Norman Brooks, Robert Lepofsky, and Richard Armstrong, the company rebranded as Azenta in December 2021 following the $3 billion divestiture of its semiconductor business. The current leadership team is led by President and CEO John P. Marotta, who joined in September 2024 with a pedigree from Patient Square Capital and PHC Holdings (Panasonic Health Care). He is supported by Executive VP and CFO Lawrence Lin, a veteran of Danaher and LivaNova, and Michael Paulo, the Chief Information & Digital Officer. The company is currently under significant influence from activist investor Quentin Koffey of Politan Capital Management, who serves on a board that also includes notable industry figures such as Chairman Frank Casal (formerly of KPMG) and Martin Madaus (The Carlyle Group).